Yuichi Fukushima

Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania.

Meiji Yasuda Life Insurance Co. is engaged in the provision of life insurance services. Its business activities include individual insurance marketing, general agent marketing, group insurance marketing, underwriting, policyholder services, claim payments, asset management and international insurance services. The company was founded on July 9, 1881 and is headquartered in Tokyo, Japan.

Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California.

Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA.

Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million.

Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.

EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023.